Guaifenesin/hydrocodone - Sovereign PharmaceuticalsAlternative Names: Guaifenesin/hydrocodone bitartrate oral solution; Guaifenesin/hydrocodone tartrate oral solution; Hydrocodone bitartrate/guaifenesin oral solution; Hydrocodone tartrate/guaifenesin oral solution; Obredon
Latest Information Update: 17 Nov 2015
At a glance
- Originator Sovereign Pharmaceuticals
- Class Antitussives; Expectorants; Morphinans; Opioid analgesics; Opioid peptides; Propylene glycols; Small molecules
- Mechanism of Action Opioid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Cough
Most Recent Events
- 06 Jan 2015 Launched for Cough in USA (PO) before January 2015